Vaxart Reports Positive Phase 1 Data for Norovirus Pill
Vaxart’s second-generation oral norovirus constructs drove a 25-fold increase in GII.4 fecal IgA and a 10-fold increase in GI.1...
New daraxorasib Data Supports Phase 3 Pancreatic Cancer Trial
In second-line metastatic PDAC, daraxonrasib monotherapy at 300 mg QD delivered a confirmed ORR of 35% in KRAS G12X...
Trethera Completes Enrollment for Phase 1 Solid Tumor Trial
Dose escalation with oral TRE-515 has reached 1,440 mg once daily—36-fold above the starting dose of 40 mg—without dose-limiting...
KFSHRC Leads Clinical Trials in Saudi Arabia with 48%
KFSHRC accounted for 48% of all clinical trials registered in Saudi Arabia in the first half of 2025, with...
FDA Authorizes Promising New Brain Cancer Drug Phase II Trial
Phase I dose escalation of NEO212 established tolerability up to 810 mg orally once daily on Days 1–5 of...
Encaleret Normalizes Calcium in Phase 2 Hypoparathyroidism
In a 10-patient Phase 2 proof-of-concept study in post-surgical hypoparathyroidism, 80% of participants on encaleret achieved concomitant normalization of...
Junshi’s Psoriasis Drug JS005 Succeeds in Phase 3 Trial
Junshi Biosciences reported that its anti–IL-17A monoclonal antibody JS005 met both co-primary endpoints—PASI 90 and sPGA 0/1 at Week...
How ICH E20 is Redefining Adaptive Clinical Trials
In the third month of a multi-arm trial for an aggressive brain cancer, the sponsor found itself facing a...
Rapport to Announce RAP-219 Phase 2a Seizure Trial Results
Rapport Therapeutics will release topline results from its Phase 2a study of RAP-219 in drug-resistant focal onset seizures on...
Gelteq’s Pioneering Allergy Gel Starts Preclinical Trial
Gelteq plans to begin a preclinical bioequivalence program in September 2025 for a gel-based oral formulation of a widely...